StockData
Altimmune, Inc. logo

Altimmune, Inc. (ALT) stock

ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30
$1.39−0.14 (-9.15%)

Close on Nov 18, 2026Market cap $270.38MP/E –Yield –

Altimmune net income

Net income is the profit left for shareholders after every expense, interest and tax.

Altimmune's net income for the twelve months ending Jun 30, 2026 was -$91.76M. For fiscal 2025 it was -$88.09M. The highest annual figure on record is -$3.44M in fiscal 2015.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$88.09M–
FY2024Dec 31, 2024-$95.06M–
FY2023Dec 31, 2023-$88.45M–
FY2022Dec 31, 2022-$84.71M–
FY2021Dec 31, 2021-$97.09M–
FY2020Dec 31, 2020-$49.04M–
FY2019Dec 31, 2019-$20.52M–
FY2018Dec 31, 2018-$39.17M–
FY2017Dec 31, 2017-$46.43M–
FY2016Dec 31, 2016-$11.09M–
FY2015Dec 31, 2015-$3.44M–
FY2014Dec 31, 2014-$9.96M–
FY2013Dec 31, 2013-$11.72M–
FY2012Dec 31, 2012-$4.92M–
FY2011Dec 31, 2011-$3.80M–
FY2010Dec 31, 2010-$34.85M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$22.83M–
Q1 FY2026Mar 31, 2026-$22.56M–
Q4 FY2025Dec 31, 2025-$27.36M–
Q3 FY2025Sep 30, 2025-$19.01M–
Q2 FY2025Jun 30, 2025-$22.15M–
Q1 FY2025Mar 31, 2025-$19.58M–
Q4 FY2024Dec 31, 2024-$23.18M–
Q3 FY2024Sep 30, 2024-$22.85M–
Q2 FY2024Jun 30, 2024-$24.64M–
Q1 FY2024Mar 31, 2024-$24.39M–
Q4 FY2023Dec 31, 2023-$31.64M–
Q3 FY2023Sep 30, 2023-$20.67M–
Q2 FY2023Jun 30, 2023-$16.06M–
Q1 FY2023Mar 31, 2023-$20.07M–
Q4 FY2022Dec 31, 2022-$21.66M–
Q3 FY2022Sep 30, 2022-$23.52M–
Q2 FY2022Jun 30, 2022-$20.11M–
Q1 FY2022Mar 31, 2022-$19.43M–
Q4 FY2021Dec 31, 2021-$23.89M–
Q3 FY2021Sep 30, 2021-$33.51M–
Q2 FY2021Jun 30, 2021-$24.83M–
Q1 FY2021Mar 31, 2021-$14.86M–
Q4 FY2020Dec 31, 2020-$10.62M–
Q3 FY2020Sep 30, 2020-$17.77M–
Q2 FY2020Jun 30, 2020-$16.77M–
Q1 FY2020Mar 31, 2020-$3.89M–
Q4 FY2019Dec 31, 2019-$4.10M–
Q3 FY2019Sep 30, 2019-$10.94M–
Q2 FY2019Jun 30, 2019-$3.39M–
Q1 FY2019Mar 31, 2019-$2.10M–
Q4 FY2018Dec 31, 2018-$24.51M–
Q3 FY2018Sep 30, 2018-$2.35M–
Q2 FY2018Jun 30, 2018-$9.14M–
Q1 FY2018Mar 31, 2018-$3.17M–
Q4 FY2017Dec 31, 2017-$8.83M-111.4%
Q3 FY2017Sep 30, 2017-$29.91M–
Q2 FY2017Jun 30, 2017-$3.11M–
Q1 FY2017Mar 31, 2017-$4.58M–
Q4 FY2016Dec 31, 2016$77.80M–
Q3 FY2016Sep 30, 2016-$4.80M–

More Altimmune figures

See a number that looks wrong?